GANX - CIK 0001819411
Gain Therapeutics, Inc. has filed 224 documents with the SEC between 2020 and 2026. The most frequent type is major company event (60 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| New insider ownership | 3 | 2021-03-17 | 2021-03-17 |
| 8-A12B | - | 2021-03-17 | - |
| Company correspondence | CORRESP | 2021-03-16 | - |
| SEC correspondence | UPLOAD | 2021-03-16 | - |
| Company correspondence | CORRESP | 2021-03-15 | - |
| Company correspondence | CORRESP | 2021-03-15 | - |
| Company correspondence | CORRESP | 2021-03-15 | - |
| S-1/A | - | 2021-03-15 | - |
| SEC correspondence | UPLOAD | 2021-03-12 | - |
| Company correspondence | CORRESP | 2021-03-10 | - |
| S-1/A | - | 2021-03-10 | - |
| SEC correspondence | UPLOAD | 2021-02-23 | - |
| Company correspondence | CORRESP | 2021-02-19 | - |
| IPO registration | S-1 | 2021-02-19 | - |
| SEC correspondence | UPLOAD | 2021-02-03 | - |
| DRSLTR | - | 2021-01-29 | - |
| DRS/A | - | 2021-01-29 | - |
| SEC correspondence | UPLOAD | 2021-01-19 | - |
| DRSLTR | - | 2021-01-08 | - |
| DRS/A | - | 2021-01-08 | - |
| SEC correspondence | UPLOAD | 2020-12-14 | - |
| DRSLTR | - | 2020-11-16 | - |
| DRS | - | 2020-11-16 | - |
| D | - | 2020-07-30 | - |